Evidence mapPaperPMID 30988077Full record

SynthesisBioscience reports2019

Are SGLT2 polymorphisms linked to diabetes mellitus and cardiovascular disease? Prospective study and meta-analysis.

Heinz Drexel, Andreas Leiherer, Christoph H Saely, Eva Maria Brandtner, Kathrin Geiger, Alexander Vonbank, Peter Fraunberger, Axel Muendlein

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in Bioscience reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Genetic polymorphisms inFrontiers in pharmacology · 2025
    Article
  3. Article
  4. The Impact of Genetic Polymorphisms on the Anti-Hyperglycemic Effect of Dapagliflozin.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024
    Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Pharmacogenetics of new classes of antidiabetic drugs.Bosnian journal of basic medical sciences · 2021
    Review
  10. Treatment Response to SGLT2 Inhibitors: From Clinical Characteristics to Genetic Variations.International journal of molecular sciences · 2021 · on this map
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 4 countries.

Heinz DrexelVorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria heinz.drexel@extern.insel.ch.ORCID 0000-0002-4677-9756
Andreas LeihererVorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria.
Christoph H SaelyDivision of Angiology, Swiss Cardiovascular Center, University Hospital of Berne, Berne, Switzerland.
Eva Maria BrandtnerVorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria.
Kathrin GeigerVorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria.
Alexander VonbankVorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria.
Peter FraunbergerMedical Central Laboratories, Feldkirch, Austria.
Axel MuendleinVorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria.
Vorarlberg Institute for Vascular Investigation and Treatment · ATUniversity Hospital of Bern · CHLandeskrankenhaus Feldkirch · ATPrivate University in the Principality of Liechtenstein · LI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhibition of the sodium glucose co-transporter 2 (SGLT2) reduces cardiovascular morbidity, and mortality in patients with type 2 diabetes mellitus (T2DM) with atherosclerotic, cardiovascular disease. So far, a link between common genetic variations of the SGLT2 encoding gene SLC5A2 and glucose homeostasis as well as cardiovascular disease has not been established. The present study, therefore, aimed to investigate SLC5A2 single nucleotide polymorphisms (SNPs) in relation to type 2 diabetes and coronary artery disease (CAD) and prospectively the incidence of cardiovascular events. We genotyped the SLC5A2 tagging SNPs rs9934336, rs3813008, and rs3116150 in a total of 1684 high risk cardiovascular patients undergoing coronary angiography, including 400 patients with T2DM. Additionally, we performed a meta-analysis combining results from the present study and the literature. Variant rs9934336 was significantly associated with decreased HbA1c (

Indexed as

AgedBlood GlucoseCardiovascular DiseasesDiabetes Mellitus, Type 2FemaleHumansMaleMiddle AgedPolymorphism, Single NucleotideProspective StudiesSodium-Glucose Transporter 2Blood GlucoseSLC5A2 protein, humanSodium-Glucose Transporter 2cardiovascular diseaseSGLT2single nucleotide polymorphismstype 2 diabetes

Identifiers

PMID30988077
PMCPMC6684948
OpenAlexW2936069588

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.